Regulatory Rapporteur - March 2025 | Regulatory Rapporteur

Regulatory Rapporteur – March 2025

Data and AI: Readiness, research and real-world impact

Organising high quality research and development data for success

AI adoption readiness: Current status and trends in regulatory organisations

Artificial intelligence and post-market surveillance

Using data to drive regulatory performance

Immunological considerations in the development of novel vaccines

The EU’s Health Technology Assessment Regulation: Overview and considerations for regulatory teams

March 2025 – Contents
Data and AI: Readiness, research and real-world impact
Organising high quality research and development data for success
AI adoption readiness: Current status and trends in regulatory organisations
Artificial intelligence and post-market surveillance
Using data to drive regulatory performance
Immunological considerations in the development of novel vaccines
The EU’s Health Technology Assessment Regulation: Overview and considerations for regulatory teams

Industry News

UK life science sector calls for more diverse workforce skills to secure future growth
To deliver cutting-edge treatments and revolutionise patient outcomes, the future life sciences sector workforce must be equipped with skills ranging from advanced scientific expertise, digital proficiency and AI-driven problem solving, according to a newly published report.
MHRA appoints new Chief Executive Officer
Lawrence Tallon has been appointed the new Chief Executive Officer at the Medicines and Healthcare products Regulatory Agency (MHRA) and will begin the role on 1 April 2025.
MHRA approves Nemolizumab for eczema patients in the UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Nemolizumab, also known as Nemluvio, to help with the treatment of atopic dermatitis (eczema) in the UK.

More news

MHRA issues guidance on post-market surveillance regulation in Great Britain

The Medicines and Healthcare products Regulatory Agency (MHRA) has published The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024: guidance on implementation

FDA releases new draft guidance on assessing artificial intelligence data

The US Food and Drug Administration (FDA) has released new draft guidance which provides a risk-based credibility framework that can be used for assessing artificial intelligence (AI) data in the drug product lifecycle.

CLICK HERE FOR ALL INDUSTRY NEWS